A research held in US resulted in a success story of several medications which can help people with alcohol use disorders maintain abstinence or reduce drinking.
Daniel Jonas, lead author of the study and professor in the department of medicine and the Cecil G. Sheps Center for Health Services Research, led a team from the RTI-UNC Evidence-based Practice Center to review published studies examining the use of drugs to treat alcohol use disorders.
They conducted a systematic review of 122 randomized controlled trials and one cohort study, after that they graded the strength of the evidence on the impact of drugs on alcohol consumption.
They found two drugs - acamprosate (brand name Campral) and oral naltrexone (brand name Revia) reduced return to drinking and improved other drinking outcomes.
Among medications used off-label i.e, those not FDA approved for alcohol use disorders, showed moderate evidance in some drinking outcomes for medicines such as topiramate and nalmefene.
Jonas said, "the health implications of preventing return to drinking and reducing alcohol consumption are substantial."
Meanwhile, he said that modeling studies have shown that such improvements would result in significant reductions in alcohol-attributable mortality, costs from health care, arrests and motor vehicle accidents.